Loading publications…
The last 5 uploaded publications
Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Rahul Aggarwal, Sylvie Rottey, Alice Bernard‐Tessier, Begoña Mellado, Takeo Kosaka, Walter M. Stadler, Lisa G. Horvath, Richard Greil, Bert H. O’Neil, Bilal A. Siddiqui, Thomas Bauernhofer, Mehmet Asım Bilen, Ferry A.L.M. Eskens, Shahneen Sandhu, Crystal Shaw, Changqing Ju, Benjamin E. Decato, Brian Yu, Ana M. Aparicio (2025). Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study. , DOI: https://doi.org/10.1158/1078-0432.ccr-25-1211.
Article62 days agoSafety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Rahul Aggarwal, Sylvie Rottey, Alice Bernard‐Tessier, Begoña Mellado, Takeo Kosaka, Walter M. Stadler, Lisa G. Horvath, Richard Greil, Bert H. O’Neil, Bilal A. Siddiqui, Thomas Bauernhofer, Mehmet Asım Bilen, Ferry A.L.M. Eskens, Shahneen Sandhu, Crystal Shaw, Changqing Ju, Benjamin E. Decato, Brian Yu, Ana M. Aparicio (2025). Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study. , DOI: https://doi.org/10.1158/1078-0432.ccr-25-1211.
Article62 days agoPhase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC).
Rahul Aggarwal, Sylvie Rottey, Alice Bernard‐Tessier, Begoña Mellado-González, Takeo Kosaka, Walter M. Stadler, Shahneen Sandhu, Brian Yu, Crystal Shaw, Chia‐Hsin Ju, Corbin G. Thompson, Ana M. Aparicio (2024). Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC).. , 42(16_suppl), DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.5012.
Article62 days agoPhase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTEimmune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).
Rahul Aggarwal, Sylvie Rottey, Ana M. Aparicio, Richard Greil, Melissa A. Reimers, Shahneen Sandhu, Yiran Zhang, Mark Salvati, Nooshin Hashemi Sadraei (2022). Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTEimmune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).. , 40(6_suppl), DOI: https://doi.org/10.1200/jco.2022.40.6_suppl.tps197.
Article62 days ago